Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567305 | 0.75 | ALDH1A1 (0.52) | KDM4E | |
| SCHEMBL5319766 | 0.75 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL9995236 | 0.71 | — | — | |
| SCHEMBL22725531 | 0.71 | AGTR1 (0.30) | — | |
| SCHEMBL9150950 | 0.71 | — | — | |
| SCHEMBL539008 | 0.68 | KDM4E (0.53) | KDM4ETYRO3DYRK1B | |
| SCHEMBL1673907 | 0.68 | SIRT2 (0.38) | NOS1DYRK1A | |
| SCHEMBL357005 | 0.68 | KDM4E (1.00) | KDM4ETYRO3DYRK1B | |
| SCHEMBL1975456 | 0.67 | JAK2 (0.33) | — | |
| SCHEMBL30110227 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4115882-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| CN-107033146-B | 6- hydrazone group -8- azapurine class compound and its preparation method and application | 北京工业大学 | 2019-04-19 | — | — | CN | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
| EP-3244891-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2017-11-22 | — | — | EP | disclosed |
| CN-107033146-A | Azapurine class compound of 6 hydrazone group 8 and its preparation method and application | 北京工业大学 | 2017-08-11 | — | — | CN | disclosed |
| WO-2016115434-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20060167017-A1 | Fungicidal triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungl, and agents containing said fungicadal triazolopyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1448564-B1 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256138-A1 | Fungicidal triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungi, and agents containing said fungicidal triazolopyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005095404-A2 | 6-(2-FLUOROPHENYL)-TRIAZOLOPYRIMIDINES, METHOD FOR PRODUCING THEM, THEIR USE FOR CONTROLLING PARASITIC FUNGI AND AGENTS CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2005-10-13 | — | — | WO | disclosed |
| US-20050176736-A1 | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances | BASF AKTIENGESELLSCHAFT (DE) | 2005-08-11 | — | — | US | disclosed |
| US-6921762-B2 | Substituted indolizine-like compounds and methods of use | AMGEN INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050090665-A1 | Fungicidal triazolopyrimidines, method for the production thereof and use thereof in controlling noxious fungi and agents containing said compounds | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1448564-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003044021-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KDM4E 3687/4885TYRO3 4848/4885DYRK1B 4788/4885 |
| US-20050090665-A1 | Fungicidal triazolopyrimidines, method for the production thereof and use thereof in controlling noxious fungi and agents containing said compounds | CBR3, CBR1, TH | KDM4E 720/4885TYRO3 59/4885DYRK1B 2223/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | KDM4E 3687/4885TYRO3 4848/4885DYRK1B 4788/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KDM4E 3687/4885TYRO3 4848/4885DYRK1B 4788/4885 |
| US-20050256138-A1 | Fungicidal triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungi, and agents containing said fungicidal triazolopyrimidines | CBR1, CBR3, DPM1 | KDM4E 2548/4885TYRO3 760/4885DYRK1B 2285/4885 |
| US-20060167017-A1 | Fungicidal triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungl, and agents containing said fungicadal triazolopyrimidines | CYP4X1, RDX, MTX1 | KDM4E 2392/4885TYRO3 592/4885DYRK1B 1976/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | KDM4E 3687/4885TYRO3 4848/4885DYRK1B 4788/4885 |
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | IL1A, IL1B, IL6 | KDM4E 2873/4885TYRO3 2235/4885DYRK1B 1451/4885 |
| US-20050176736-A1 | Fungicidal triazolopyrimidines, methods for producing the same, use thereof for combating harmful fungi and agents containing said substances | CBR1, CBR3, HAO1 | KDM4E 4617/4885TYRO3 974/4885DYRK1B 2599/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | KDM4E 3687/4885TYRO3 4848/4885DYRK1B 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.